Description
Product Usage Information
Flow Cytometry (Fixed/Permeabilized): 1:200 - 1:800
Flow Cytometry (Live): 1:200 - 1:800
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Flow Cytometry (Fixed/Permeabilized), Flow Cytometry (Live)
Specificity / Sensitivity
LILRB4/CD85k (F3G1D) Rabbit Monoclonal Antibody recognizes endogenous levels of total LILRB4/CD85k protein. This antibody does not cross-react with other LILRB/CD85 proteins.
Species Reactivity: Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the amino terminus of human LILRB4/CD85k protein.
Background
The leukocyte Ig-like receptor subfamily B (LILRB) are type-I transmembrane glycoproteins containing ligand-binding extracellular IgG-like domains and immunoreceptor tyrosine-based inhibition motifs (ITIMS) within the cytoplasmic domain, which recruit SHP protein tyrosine phosphatases, leading to transduction of signals that inhibit immune cell activation. Encoded within a region of chromosome 19 known as the leukocyte receptor complex, the LILRB subfamily of inhibitory receptors consists of LILRB1 to LILRB5, also referred to as CD85J, CD85D, CD85A, CD85K, and CD85C, respectively (1). There is mounting evidence that LILRBs function, in part, as a novel class of immune checkpoint receptors and support tumor growth through the transmission of inhibitory signals upon engagement of ligands expressed on tumor cells (2). LILRB4 is expressed on various immune cell types, such as monocytes, macrophages, dendritic cells (DCs), mast cells, B cells, T cells, and natural killer (NK) cells (3,4). LILRB4 expression is elevated in leukemia cells and promotes an immunosuppressive microenvironment by inhibiting T cell activity (5). LILRB4 expression is also associated with multiple myeloma (MM), and knockdown of LILRB4 has been shown to restrict MM proliferation (6,7). Knockout of LILRB4 or treatment with an anti-LILRB4 antibody has also been shown to reduce tumor burden in various murine tumor models, further suggesting that LILRB4 can be targeted for immunotherapies (8).
Alternate Names
CD85 antigen-like family member K; CD85K; HM18; ILT-3; ILT3; Immunoglobulin-like transcript 3; leucocyte Ig-like receptor B4; leukocyte immunoglobulin like receptor B4; Leukocyte immunoglobulin-like receptor 5; Leukocyte immunoglobulin-like receptor subfamily B member 4; leukocyte immunoglobulin-like receptor subfamily B member 4 soluble isoform; leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4; leukocyte immunoglobulin-like receptor, subfamily B, member 4; LILRB4; LILRB5; LIR-5; LIR5; LIRB4; Monocyte inhibitory receptor HM18
